Q1 2014's Top Pharma & Biotech M&A Deals
The global pharmaceuticals industry has witnessed significant change in the last few years from patent expiry to declining product pipelines. In addition the cost of developing and marketing a new drug continues to soar. One way pharmaceutical and biotech companies are dealing with these challenges is by turning to mergers and acquisitions as a way to improve pipelines, efficiency and enter new markets. A recent KPMG 2014 M&A Survey Report predicts healthcare, pharmaceuticals and life scienc...
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.